AstraZeneca is paying $160 million for FibroGen’s China business, giving the U.K.-based Big Pharma the regional rights to oral anemia drug roxadustat. The two companies' relationship around ...

FibroGen sells its China unit to AstraZeneca for about $160M, strengthening its cash position and extending its financial runway into 2027. AstraZeneca gains full rights to roxadustat in China ...

The FDA posted to its site the observations made during an inspection of an AstraZeneca (AZN) manufacturing center that was conducted from May 30, 2024 to June 7, 2024, including manufacturing and ...

AstraZeneca's lengthy and turbulent development of CTLA4 inhibitor tremelimumab has at least led to a regulatory approval as part of a combination therapy for advanced liver cancer.

Maria joined AstraZeneca in 2017 as head of Respiratory, Inflammation & Autoimmunity in the Innovative Medicines and Early Development (IMED) Biotech Unit. In her role she leads early-stage ...

Eli Lilly bets big on weight-loss pill with $550 million inventory stockpile Healthcare & Pharmaceuticalscategory· February 20, 2025 AstraZeneca will buy longtime partner FibroGen's China unit ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

AstraZeneca Pharma India Ltd., incorporated in the year 1979, is a Mid Cap company (having a market cap of Rs 17,439.50 Crore) operating in Pharmaceuticals sector. AstraZeneca Pharma India Ltd. key ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.